Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E17.30 EPS (ttm)5.31 Insider Own9.30% Shs Outstand2.52B Perf Week3.29%
Market Cap232.01B Forward P/E16.60 EPS next Y5.54 Insider Trans-0.80% Shs Float2.50B Perf Month12.07%
Income12.45B PEG2.53 EPS next Q1.20 Inst Own12.10% Short Float0.11% Perf Quarter9.77%
Sales51.64B P/S4.49 EPS this Y66.90% Inst Trans0.99% Short Ratio1.02 Perf Half Y19.65%
Book/sh20.37 P/B4.51 EPS next Y10.10% ROA8.70% Target Price99.50 Perf Year38.50%
Cash/sh2.82 P/C32.62 EPS next 5Y6.83% ROE17.60% 52W Range64.76 - 91.98 Perf YTD19.58%
Dividend2.83 P/FCF44.37 EPS past 5Y7.70% ROI11.50% 52W High0.80% Beta0.59
Dividend %3.08% Quick Ratio0.80 Sales past 5Y0.20% Gross Margin69.00% 52W Low43.17% ATR1.15
Employees105000 Current Ratio0.90 Sales Q/Q2.10% Oper. Margin26.60% RSI (14)83.98 Volatility0.92% 1.03%
OptionableYes Debt/Eq0.65 EPS Q/Q-4.80% Profit Margin23.90% Rel Volume0.73 Prev Close91.91
ShortableYes LT Debt/Eq0.48 EarningsJul 24 BMO Payout55.20% Avg Volume2.68M Price92.72
Recom1.50 SMA205.62% SMA5010.94% SMA20015.91% Volume448,777 Change0.88%
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Jun-20-19 09:29AM  This would be the worst-case scenario for health stocks, according to UBS MarketWatch
Jun-19-19 09:30AM  NVS or NVO: Which Is the Better Value Stock Right Now? Zacks
Jun-18-19 05:11PM  Online pharmacy flags possible new impurity in blood pressure drug Reuters
09:45AM  Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status Zacks
09:41AM  Alcon Inc. -- Moody's assigns Baa2 ratings to Alcon Inc.'s unsecured debt facilities Moody's
08:03AM  Roche's Rozlytrek Gets Approval in Japan for Solid Tumors Zacks
Jun-17-19 05:26PM  J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study Zacks
03:41PM  Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz Zacks
Jun-13-19 10:35PM  Bluebird Bio prices gene therapy at nearly $1.8m Financial Times
05:40PM  Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris Zacks
02:34PM  Top Analyst Reports for Visa, Netflix & Accenture Zacks
09:36AM  Ligand Inks Oncology Drug Discovery Deal With PhoreMost Zacks
07:30AM  A Stock Fund Challenges the Definition of Growth. Its Paying Off. Barrons.com
Jun-12-19 06:33PM  Roche's Rituxan Gets Priority Review for Blood Disorder Zacks
06:21PM  Novartis Reports Data on Cosentyx for Psoriatic Arthritis Zacks
Jun-11-19 02:50PM  Stoke Therapeutics boosts IPO goal by 40 percent American City Business Journals
Jun-10-19 05:30PM  Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug Zacks
11:48AM  Curium Bidco S.a.r.l -- Moody's assigns B2 CFR to Curium Bidco S.a.r.l.; outlook stable Moody's
09:39AM  Roche Receives FTC Request for Further Data on Spark Buyout Zacks
Jun-07-19 05:00PM  Celgene's Filing for Ozanimod Accepted for Review in US/EU Zacks
12:25PM  Sanofi's Leadership Transition: What You Need To Know Benzinga
11:53AM  New Sanofi CEO 2019: 8 Things to Know About Paul Hudson InvestorPlace
11:28AM  Heres What Hedge Funds Think About Novartis AG (NVS) Insider Monkey
10:59AM  Sanofi Taps Novartis Executive as CEO in Race for New Drugs Bloomberg
09:09AM  Novartis Appoints New Pharma Unit Head, Gives Other Updates Zacks
07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
03:51AM  Sanofi appoints top Novartis executive as new chief Financial Times
Jun-06-19 11:20PM  StockBeat: Markets Rise as Miserable German Data Boost QE Hopes Investing.com
03:28PM  Alnylam Completes Rolling NDA Submission to FDA for Givosiran Zacks
03:26PM  Incyte Begins Phase III Study for Treatment of Duct Cancer Zacks
09:09AM  Was ASCO Quieter for Big Drug/Biotech Stocks This Year? Zacks
07:37AM  The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering Benzinga
Jun-05-19 08:10AM  Continued Smart M&A Moves Will Help Canopy Stock Break Out InvestorPlace
Jun-04-19 01:03PM  Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist® PR Newswire
10:32AM  Aduro Stock Crashes After ASCO Updates on Cancer Candidate Zacks
Jun-03-19 11:52AM  Novartis (NVS) Announces Various Data Presentations at ASCO Zacks
09:42AM  Roche Presents Positive Data on Xolair & Updates From ASCO Zacks
09:11AM  Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO Zacks
01:19AM  Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials PR Newswire
Jun-01-19 09:53AM  Were Hedge Funds Right About Souring On Pfizer Inc. (PFE)? Insider Monkey
07:30AM  Novartis hopes Kisqali data will help narrow gap to blockbuster rival Reuters
May-31-19 01:45PM  Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates Benzinga
01:31PM  Nationwide Children's invented 'the most expensive drug ever,' but the hospital didn't set the price American City Business Journals
01:28PM  FDA approval of life-saving Nationwide Children's invention bodes well for ongoing gene therapy research American City Business Journals
10:39AM  Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous? Motley Fool
09:07AM  Biogen Reports Interim Phase III Data on Diroximel Fumarate Zacks
04:05AM  Novartis (NVS) Reports Positive Phase III Data on Asthma Drug Zacks
May-30-19 02:34PM  Save the Date: 11 Biotech Stocks to Put on Your Radar Kiplinger
11:02AM  PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts Zacks
08:15AM  Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much Motley Fool
07:33AM  The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug Benzinga
May-29-19 12:37PM  The Only 3 Marijuana Stocks You Need to Own InvestorPlace
May-28-19 01:47PM  FDA approves most expensive gene therapy ever and here is its connection to Penn American City Business Journals
11:48AM  Conatus Down More Than 60% in the Past 90 Days: Here's Why Zacks
08:48AM  Market Morning: Huawei Fumes, Volkswagen Feuds, Novartis Wins, Farage Threatens Market Exclusive
07:00AM  A Closer Look at Vanguard Global ESG Select Stock Morningstar
May-27-19 11:10AM  Novartis Gene Therapy Crosses The $2 Million Mark Will Others Follow? Investor's Business Daily
10:20AM  Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy Zacks
09:17AM  Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi Zacks
May-26-19 06:31PM  Can Novartis Convince Insurers a $2.1 Million Gene Therapy Is a Great Deal? Motley Fool
May-24-19 07:46PM  Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio Motley Fool
07:39PM  Novartis $2 million gene therapy for rare disorder is world's most expensive drug Reuters
07:39PM  For Anderson family, an early bet on SMA gene therapy Reuters
06:48PM  Novartis $2 mln gene therapy for rare disorder is world's most expensive drug Reuters
05:52PM  At $2M, priciest ever medicine treats fatal genetic disease Associated Press
05:26PM  For Anderson family, an early bet on SMA gene therapy Reuters
04:44PM  Novartis gets FDA nod for advanced breast-cancer treatment MarketWatch
04:28PM  Novartis' breast cancer treatment wins FDA approval Reuters
04:04PM  4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS InvestorPlace
03:30PM  Novartis' breast cancer treatment wins FDA approval Reuters
03:10PM  No Miracle Drug Should Cost $2.1 Million Bloomberg
02:44PM  FDA approves Novartis gene therapy for rare genetic disorder CNBC Videos
02:38PM  The Funded: One Bay Area biotech goes public while another files IPO plans American City Business Journals
01:30PM  Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval American City Business Journals
01:09PM  AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA) PR Newswire
01:03PM  FDA approves Novartis' $2.1 million gene therapy making it the world's most expensive drug CNBC
12:49PM  U.S. approves Novartis gene therapy for rare, deadly muscle disorder Reuters
12:23PM  Highlights from CNBC's Healthy Returns conference CNBC
09:30AM  Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates Zacks
May-23-19 03:46PM  Novartis Reports Data on Asthma Drug, Update from Annual Meet Zacks
02:17PM  Tilray Stock Still Hasnt Bottomed InvestorPlace
11:58AM  Novartis CEO says data quality, lagging innovation crimp China M&A Reuters
11:42AM  (Re)Focusing Big Pharma: Novartis CEO Vasant Narasimhan with Jim Cramer at Healthy Returns CNBC Videos
11:02AM  After IFM buy, Novartis looks to more early stage biotech M&A American City Business Journals
10:03AM  Alphabet to Aid Pharma Giants Enhance Clinical Trial Process Zacks
09:22AM  Novartis CEO sees chance to accelerate profit margin target Reuters
01:37AM  Novartis has 25 blockbusters in the pipeline: CEO Reuters
May-22-19 05:54PM  Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range Reuters
05:21PM  Novartis CEO plans gene therapy price 'far lower' than $4 mln to $5 mln range Reuters
09:31AM  Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point TheStreet.com
07:34AM  The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
May-21-19 07:52PM  Cramer Remix: The cannabis stocks I'm eyeing CNBC
06:56PM  Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO CNBC Videos
06:55PM  Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO CNBC
06:50PM  Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches CNBC Videos
06:24PM  Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches CNBC
01:20PM  These 3 Major Drug Manufacturers Are Strong Performers GuruFocus.com
11:46AM  Novartis CEO says cannabis isn't a focus despite Tilray partnership CNBC
10:08AM  Novartis CEO on single-payer health care: It is not the right move for America CNBC Videos
May-20-19 04:14PM  Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study Zacks
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; TRIO; and Verily. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerMay 28Buy14.00168,6302,360,8201,769,641May 30 09:27 PM
Novartis Bioventures Ltd10% OwnerApr 26Sale1.03138,704142,8654,049,804Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 25Sale1.03563,096579,9894,188,508Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 24Sale1.0316,40316,8954,751,604Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 23Sale1.0327,55428,3814,768,007Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 22Sale0.977,1006,8874,795,561Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 15Sale0.9928,79428,5064,802,661Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 12Sale1.0430,90832,1444,831,455Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 11Sale1.0857,43862,0334,862,363Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 10Sale1.09140,230152,8514,919,801Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 09Sale1.0132,99133,3215,060,031Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 08Sale1.0227,52528,0765,093,022Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 05Sale1.0224,66125,1545,120,547Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 04Sale1.0147,90048,3795,145,208Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 03Sale0.9658,03355,7125,193,108Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 02Sale0.9751,75450,2015,251,141Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale0.95116,909111,0645,302,895Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale1.9020,61039,1592,079,394Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale1.85106,540197,0992,100,004Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale0.9163,10057,4215,419,804Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 28Sale0.9488,83583,5055,482,904Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 27Sale0.9950,74950,2425,571,739Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 26Sale1.01177,762179,5405,622,488Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 15Sale1.9243,80084,0962,206,544Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 14Sale1.8813,80025,9442,250,344Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 13Sale2.12132,738281,4052,264,144Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerAug 20Sale2.3020,38846,8922,396,882Aug 22 04:34 PM
Novartis Bioventures Ltd10% OwnerAug 20Sale3.905,30020,6705,800,250Aug 22 04:07 PM
Novartis Bioventures Ltd10% OwnerAug 17Sale2.108,70018,2702,417,270Aug 20 05:12 PM
Novartis Bioventures Ltd10% OwnerAug 16Sale2.108,80818,4972,425,970Aug 20 05:12 PM
Novartis Bioventures Ltd10% OwnerAug 15Sale2.152,6355,6652,434,778Aug 16 04:18 PM
Novartis Bioventures Ltd10% OwnerAug 14Sale2.263,3007,4582,437,413Aug 16 04:18 PM
Novartis Bioventures Ltd10% OwnerAug 13Sale2.361,6003,7762,440,713Aug 14 05:05 PM
Novartis Bioventures Ltd10% OwnerAug 10Sale2.445,61513,7012,442,313Aug 14 05:05 PM
Novartis Bioventures Ltd10% OwnerAug 09Sale2.482355832,447,928Aug 10 04:29 PM
Novartis Bioventures Ltd10% OwnerAug 08Sale2.781,0002,7802,448,163Aug 10 04:29 PM
Novartis Bioventures Ltd10% OwnerAug 07Sale2.971,7395,1652,449,163Aug 08 04:21 PM
Novartis Bioventures Ltd10% OwnerAug 06Sale3.022,9428,8852,450,902Aug 08 04:21 PM
Novartis Bioventures Ltd10% OwnerAug 02Sale3.334,70215,6582,453,844Aug 06 04:22 PM
Novartis Bioventures Ltd10% OwnerAug 01Sale3.228,18126,3432,458,546Aug 02 04:33 PM
Novartis Bioventures Ltd10% OwnerJul 31Sale3.074,50013,8152,466,727Aug 02 04:33 PM
Novartis Bioventures Ltd10% OwnerJul 30Sale3.272,0006,5402,471,227Jul 31 04:16 PM
Novartis Bioventures Ltd10% OwnerJul 27Sale3.386,45821,8282,473,227Jul 31 04:16 PM
Novartis Bioventures Ltd10% OwnerJul 26Sale3.637,93728,8112,479,685Jul 27 04:21 PM
Novartis Bioventures Ltd10% OwnerJul 25Sale3.8412,46047,8462,487,622Jul 27 04:21 PM
Novartis Bioventures Ltd10% OwnerJul 24Sale4.117002,8772,500,082Jul 25 04:35 PM
Novartis Bioventures Ltd10% OwnerJul 23Sale4.2530,600130,0502,500,782Jul 25 04:35 PM
Novartis Bioventures Ltd10% OwnerJul 17Sale4.7112,50058,8752,531,382Jul 18 04:17 PM
Novartis Bioventures Ltd10% OwnerJul 16Sale5.153001,5452,543,882Jul 18 04:17 PM